Blog
RSS FeedPosted by Michael Wonder on 13 May 2020
Seattle Genetics announces the approval of Tukysa (tucatinib) in Switzerland for the treatment of patients with metastatic HER2-positive breast cancer
12 May 2020 - First approval for Tukysa outside of the U.S. ...
Posted by Michael Wonder on 23 Apr 2020
Swift COVID-19 vaccine within reach, say Swiss scientists
21 April 2020 - A team of researchers at the University of Bern is hoping to be the first to ...
Posted by Michael Wonder on 21 Apr 2020
Swiss deal on cystic fibrosis drugs could change price negotiations
21 April 2020 - The deal is expected to help 400 eligible cystic fibrosis patients in Switzerland. ...
Posted by Michael Wonder on 07 Apr 2020
Novartis announces first European donation of hydroxychloroquine to Switzerland
3 April 2020 - Novartis has committed to making a global donation of up to 130 million doses of the anti-malarial ...
Posted by Michael Wonder on 04 Apr 2020
Swiss Government expands powers to force firms to make supplies to fight COVID-19
3 April 2020 - The Swiss government on Friday boosted its powers to order companies to raise production of critical ...
Posted by Michael Wonder on 13 Nov 2019
FDA’s Project Orbis may expand to Singapore and Switzerland
12 November 2019 - The US FDA may expand a pilot project that allows for simultaneous drug approval decisions from ...
Posted by Michael Wonder on 10 Oct 2019
Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana (canagliflozin) in fast-track procedure
9 October 2019 - The CREDENCE renal outcomes study, which was stopped early in July 2018 owing to positive efficacy findings, ...
Posted by Michael Wonder on 25 Mar 2019
Mavenclad (cladribine tablets) approved as the first short-course oral treatment for relapsing remitting multiple sclerosis in Switzerland
25 March 2019 - Approval based on extensive clinical development program capturing more than 10,000 patient years of safety data and ...
Posted by Michael Wonder on 21 Feb 2019
High pharma margins squeeze health care systems
19 February 2019 - The WHO found that for every dollar invested in cancer research, pharmaceutical companies earned on average $14.50 ...
Posted by Michael Wonder on 28 Nov 2018
Octapharma receives Swissmedic approval for fibryga to treat congenital and acquired fibrinogen deficiencies
26 November 2018 - Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorisation to its new ...
Posted by Michael Wonder on 02 Nov 2018
Federal office decides drug price cuts
2 November 2018 - There will be an average drop of almost 20% in the price of 288 medicines from ...
Posted by Michael Wonder on 22 Oct 2018
Novartis leukaemia drug approved in Switzerland
22 October 2018 - Basel-based pharmaceutical company Novartis has received approval for its personalised cell therapy Kymriah in Switzerland. Children ...
Posted by Michael Wonder on 02 Oct 2018
Swissmedic approves Ameluz in combination with daylight photodynamic therapy in Switzerland
1 October 2018 - Biofrontera announced today that Swissmedic, the Swiss national approval and supervisory authority for drugs and medical ...
Posted by Michael Wonder on 17 Sep 2018
Dutch, Swiss regulators forge agreement on data exchange
14 September 2018 - The heads of the Netherland’s Medicines Evaluation Board and Swissmedic have signed a memorandum of understanding ...
Posted by Michael Wonder on 05 Jul 2018
International work-sharing pilot - apalutamide (Erlyand)
5 July 2018 - Apalutamide (Erlyand) is the first medicine to be registered on the Australian Register of Therapeutic Goods ...